JP2017502056A - 肝障害の治療方法 - Google Patents

肝障害の治療方法 Download PDF

Info

Publication number
JP2017502056A
JP2017502056A JP2016545301A JP2016545301A JP2017502056A JP 2017502056 A JP2017502056 A JP 2017502056A JP 2016545301 A JP2016545301 A JP 2016545301A JP 2016545301 A JP2016545301 A JP 2016545301A JP 2017502056 A JP2017502056 A JP 2017502056A
Authority
JP
Japan
Prior art keywords
compound
formula
administered
metabolite
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016545301A
Other languages
English (en)
Japanese (ja)
Inventor
和子 松田
和子 松田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicinova Inc
Original Assignee
Medicinova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicinova Inc filed Critical Medicinova Inc
Publication of JP2017502056A publication Critical patent/JP2017502056A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2016545301A 2014-01-10 2015-01-07 肝障害の治療方法 Pending JP2017502056A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/152,924 US8962687B2 (en) 2012-12-05 2014-01-10 Method of treating liver disorders
US14/152,924 2014-01-10
PCT/US2015/010479 WO2015105874A1 (en) 2014-01-10 2015-01-07 Method of treating liver disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019152601A Division JP2019218379A (ja) 2014-01-10 2019-08-23 肝障害の治療方法

Publications (1)

Publication Number Publication Date
JP2017502056A true JP2017502056A (ja) 2017-01-19

Family

ID=50826043

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016545301A Pending JP2017502056A (ja) 2014-01-10 2015-01-07 肝障害の治療方法
JP2019152601A Pending JP2019218379A (ja) 2014-01-10 2019-08-23 肝障害の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019152601A Pending JP2019218379A (ja) 2014-01-10 2019-08-23 肝障害の治療方法

Country Status (10)

Country Link
US (2) US8962687B2 (enExample)
EP (1) EP3091972B1 (enExample)
JP (2) JP2017502056A (enExample)
KR (1) KR102352729B1 (enExample)
CN (1) CN105934243A (enExample)
BR (1) BR112016015712A8 (enExample)
CA (1) CA2935933C (enExample)
ES (1) ES2917982T3 (enExample)
TW (1) TW201609081A (enExample)
WO (1) WO2015105874A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2950909C (en) * 2014-06-02 2023-03-28 Medicinova, Inc. Method of inhibiting or treating fibrosis
WO2016085994A1 (en) * 2014-11-26 2016-06-02 Medicinova, Inc. Ibudilast and telmisartan for treating non-alcoholic fatty liver disease, non alcoholic steatohepatitis, and advanced non alcoholic steatohepatitis
KR102399254B1 (ko) 2016-09-28 2022-05-17 아이거 바이오파마슈티컬스 인코포레이티드 비-알코올성 지방간염의 치료를 위한 방법 및 약제학적 조성물
CN110099690B (zh) * 2017-11-30 2021-10-26 北京通复堂生物科技股份有限公司 适于非酒精性脂肪性肝病和/或非酒精性脂肪性肝炎和/或肝脂肪变性的治疗的复方制剂
JP2024522030A (ja) * 2021-05-28 2024-06-10 メディシノバ・インコーポレイテッド フェノキシアルキルカルボン酸誘導体、およびトリグリセリドレベルを低下させることにおけるその使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013119550A (ja) * 2011-12-08 2013-06-17 Medicinova Inc 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の処置方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2585246A1 (fr) 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
US4788055A (en) 1985-12-09 1988-11-29 Ciba-Geigy Corporation Resinate sustained release dextromethorphan composition
GB8613688D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4816264A (en) 1986-06-06 1989-03-28 Warner-Lambert Company Sustained release formulations
FI76778C (fi) 1986-09-22 1988-12-12 Kyro Oy Foerfarande och anordning foer transport av glasskivor under upphettning och haerdning.
US4985585A (en) 1988-03-07 1991-01-15 Kyorin Pharmaceutical Co., Ltd. Phenoxyalkylcarboxylic acid derivatives and process for their preparations
US4996047A (en) 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
CA2002492A1 (en) 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5290812A (en) 1991-01-18 1994-03-01 Kyorin Pharmaceutical Co., Ltd. Phenoxyalkylcarboxylic acid derivatives and process of preparing the same
US7060854B2 (en) 2003-06-24 2006-06-13 Medicinova, Inc. Process for making polymorphic form A of 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid
US7064146B2 (en) 2003-06-24 2006-06-20 Medicinova, Inc. Pharmaceutical compositions of isolated orthorhombic crystalline 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013119550A (ja) * 2011-12-08 2013-06-17 Medicinova Inc 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の処置方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
肝臓, vol. 25(2), JPN6018032950, 1984, pages 204 - 209, ISSN: 0003865189 *

Also Published As

Publication number Publication date
EP3091972B1 (en) 2022-06-01
CA2935933A1 (en) 2015-07-16
JP2019218379A (ja) 2019-12-26
KR102352729B1 (ko) 2022-01-18
US20150209314A1 (en) 2015-07-30
CA2935933C (en) 2022-06-28
WO2015105874A1 (en) 2015-07-16
ES2917982T3 (es) 2022-07-12
EP3091972A4 (en) 2017-08-23
US8962687B2 (en) 2015-02-24
BR112016015712A2 (pt) 2017-08-08
KR20160099716A (ko) 2016-08-22
EP3091972A1 (en) 2016-11-16
TW201609081A (zh) 2016-03-16
BR112016015712A8 (pt) 2018-04-17
US20140155484A1 (en) 2014-06-05
CN105934243A (zh) 2016-09-07

Similar Documents

Publication Publication Date Title
JP2019218379A (ja) 肝障害の治療方法
JP6608404B2 (ja) 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の処置方法
US20240382512A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
JP7033317B2 (ja) 白内障の予防剤、治療剤、およびこれらを製造するためのｈａｔ阻害剤の使用
JP6672173B2 (ja) 進行した非アルコール性脂肪性肝炎の治療方法
US12239620B2 (en) Methods to decrease triglyceride synthesis in the liver
US20150320705A1 (en) Method of inhibiting or treating amyotrophic lateral sclerosis with phenoxyalkylcarboxylic acids

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160916

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180822

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180828

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190423

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20190823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190823

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200630

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201110

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20201201

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210105

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210105